Effect of edaravone on cerebral vasospasm following experimental subarachnoid hemorrhage

Journal of Stroke and Cerebrovascular Diseases

Volumn 12, Issue 1, 2003, Pages 17-21

  Nakagomi, Tadayoshi ^a   Yamakawa, Kenta ^b   Sasaki, Tomio ^c   Saito, Isamu ^d   Takakura, Kintomo ^e  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Yamakawa Otorhinolaryngological Clinic   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Edaravone; Free radical scavenger; Subarachnoid hemorrhage; Vasospasm

Indexed keywords

NORPHENAZONE; OXYHEMOGLOBIN; SCAVENGER;

ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASILAR ARTERY; BOLUS INJECTION; BRAIN VASOSPASM; CONTINUOUS INFUSION; CONTROLLED STUDY; DOG; DRUG EFFICACY; DRUG MECHANISM; LIPID PEROXIDATION; NONHUMAN; PRIORITY JOURNAL; SUBARACHNOID HEMORRHAGE;

EID: 0037219538     PISSN: 10523057     EISSN: None     Source Type: Journal    
DOI: 10.1053/jscd.2003.2     Document Type: Article

References (35)

1. Dorsch NWC, King MT. A review of cerebral vasospasm in aneurysmal subarachnoid hemorrhage. J Clin Neurosci 1994;1:19-26.
2. Gutteridge JMC. Iron promoters of the Fenton reaction and lipid peroxidation can be released from hemoglobin by peroxides. FEBS Lett 1986;201:291-295.
3. Kellogg EW III, Fridovich I. Liposome oxidation and erythrocyte lysis by enzymically generated superoxide and hydrogen peroxide. J Biol Chem 1977;252:6721-6728.
4. Winterbourn CC, McGrath BM, Carrell RW. Reactions involving superoxide and normal and unstable haemoglobin. Biochem J 1976;155:493-502.
5. Asano T, Sasaki T, Koide T, et al. Experimental evaluation of the beneficial effect of an antioxidant on cerebral vasospasm. Neurol Res 1984;6:49-53.
6. Asano T, Takakura K, Sano K, et al. Effects of a hydroxy radical scavenger on delayed ischemic neurological deficits following aneurysmal subarachnoid hemorrhage: results of a multicenter, placebo-controlled double-blind trial. J Neurosurg 1996;84:792-803.
7. Echlin F. Experimental vasospasm, acute and chronic, due to blood in the subarachnoid space. J Neurosurg 1971;35:646-656.
8. Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery 1980;6:1-9.
9. Macdonald RI, Weir BKA. A review of hemoglobin and the pathogenesis of cerebral vasospasm. Stroke 1991;22: 971-982.
10. Mayberg MR, Okada T, Bark DH. The role of hemoglobin in arterial narrowing after subarachnoid hemorrhage. J Neurosurg 1990;72:634-640.
11. Saito I, Asano T, Sano K, et al. Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage. Neurosurgery 1998;42:269-277.
12. Tanishima T. Cerebral vasospasm: contractile activity of hemoglobin in isolated canine basilar arteries. J Neurosurg 1980;53:787-793.
13. Murota S, Morita I, Suda N. The control of vascular endothelial injury. Ann NY Acad Sci 1990;598:182-187.
14. Watanabe T, Morita I, Nishi H, et al. Preventive effect of MCI-186 on 15-HPETE induced vascular endothelial cell injury in vitro. Prostaglandins Leukot Essent Fatty Acids 1988;33:81-87.
15. Watanabe T, Yuki S, Egawa M, et al. Protective effects of MCI-186 on cerebral ischemia: Possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther 1994;268:1597-1604.
16. Abe K, Yuki S, Kogure K. Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger. Stroke 1988;19:480-485.
17. Kawai H, Nakai H, Suga M, et al. Effects of a novel free radical scavenger, MCI-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J Pharmacol Exp Ther 1997;281:921-927.
18. Mizuno A, Umemura K, Nakashima M. Inhibitory effect of MCI-186, a free radical scavenger, on cerebral ischemia following rat middle cerebral artery occlusion. Gen Pharmacol 1998;30:575-578.
19. Kassell NF, Peerless SJ, Durward QJ, et al. Treatment of ischemic deficits from vasospasm with intravascular volume expansion and induced arterial hypertension. Neurosurgery 1982;11:337-343.
20. Origitano TC, Wascher TM, Reichman OH, et al. Sustained increased cerebral blood flow with prophylactic hypertensive hypervolemic hemodilution (triple-H therapy) after subarachnoid hemorrhage. Neurosurgery 1990;27:729-739.
21. Feigin VL, Rinkel GJE, Algra A, et al. Calcium antagonists for aneurysmal subarachnoid hemorrhage [Cochrane Review]. Cochrane Database of Systemic Reviews 2000; Issue 2. Oxford: Update Software.
22. Flamm ES, Adams HP, Beck DW, et al. Dose-escalation study of intravenous nicardipine in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 1988;68: 393-400.
23. Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid hemorrhage: British aneurysmal nimodipine trial. Br Med J 1989;298:636-642.
24. Shibuya M, Suzuki Y, Sugita K, et al. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: results of a prospective placebo-controlled double-blind trial. J Neurosurg 1992;74:571-577.
25. Findley JM, Kassell NF, Weir BKA, et al. A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm. Neurosurgery 1995;37:168-178.
26. Kodama N, Sasaki T, Kawakami M, et al. Cisternal irrigation therapy with urokinase and ascorbic acid for prevention of vasospasm after aneurysmal subarachnoid hemorrhage. Surg Neurol 2000;53:110-118.
27. Mizoi K, Yoshimoto T, Takahashi M, et al. Prospective study on the prevention of cerebral vasospasm by intrathecal fibrinolytic therapy with tissue type plasminogen activator. J Neurosurg 1993;78:430-437.
28. Nakagomi T, Takagi K, Narita K, et al. Cisternal washing therapy for the prevention of cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Acta Neurochir 2001;77:161-165 (suppl)
29. Ohman J, Servo A, Heiskanen O. Effect of intrathecal fibrinolytic therapy on clot lysis and vasospasm in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 1991;75:197-201.
30. Sasaki T, Ohta T, Kikuchi H, et al. A phase II clinical trial of recombinant human tissue-type plasminogen activator against cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery 1994;315:597-605.
31. Zabranski JM, Spetzler RF, Lee HKS, et al. Phase I trial of tissue plasminogen activator for the prevention of vasospasm in patients with subarachnoid hemorrhage. J Neurosurg 1991;75:189-196.
32. Finn SS, Stephensen SA, Miller CA, et al. Observations on the perioperative management of aneurysmal subarachnoid hemorrhage. J Neurosurg 1986;65:48-62.
33. Zuccarello M, Marsch JT, Schmitt G, et al. Effect of the 21-aminosteroid U-74006F on cerebral vasospasm following subarachnoid hemorrhage. J Neurosurg 1989;71: 98-104.
34. Watanabe T, Nishiyama M, Hori T, et al. Ebselen (DR3305) ameliorates delayed cerebral vasospasm in a canine two-hemorrhage model. Neurol Res 1997;19:563-565.
35. Kassell NF, Haley EC Jr, Apperson-Hansen C, et al. Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New Zealand. J Neurosurg 1996;84:221-228.